Although the initiation of an anti-TNF agent in a patient with a mild case of COVID-19 seems safe and potentially beneficial, it remains important to note that more cases are required to properly assess which patients might benefit from its use as a therapeutic agent for COVID-19. This evidence concerns the gene TNF and COVID-19.